I M Kramer

552 total citations
9 papers, 481 citations indexed

About

I M Kramer is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, I M Kramer has authored 9 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Immunology. Recurrent topics in I M Kramer's work include Neutrophil, Myeloperoxidase and Oxidative Mechanisms (3 papers), S100 Proteins and Annexins (3 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). I M Kramer is often cited by papers focused on Neutrophil, Myeloperoxidase and Oxidative Mechanisms (3 papers), S100 Proteins and Annexins (3 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). I M Kramer collaborates with scholars based in Netherlands, Germany and United Kingdom. I M Kramer's co-authors include Dirk Roos, Hans‐Peter Lipp, R.L. van der Bend, A. J. Verhoeven, Ron S. Weening, Siegfried W. de Laat, I. Koornneef, Wim J. van Blitterswijk, Anton T. J. Tool and R. S. Weening and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

I M Kramer

8 papers receiving 469 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
I M Kramer Netherlands	8	274	208	88	51	47	9	481
Shin Akakura United States	14	388 1.4×	253 1.2×	132 1.5×	84 1.6×	92 2.0×	22	757
Mitsuru Machide Japan	11	228 0.8×	108 0.5×	98 1.1×	101 2.0×	29 0.6×	13	543
Tom Büchse Germany	8	245 0.9×	161 0.8×	71 0.8×	90 1.8×	26 0.6×	10	446
Susan Adams United States	8	313 1.1×	213 1.0×	51 0.6×	108 2.1×	55 1.2×	10	593
Edwige Voisset France	10	252 0.9×	227 1.1×	43 0.5×	106 2.1×	28 0.6×	16	594
Luciana M. Laguinge United States	7	309 1.1×	74 0.4×	36 0.4×	122 2.4×	40 0.9×	9	471
Graham Craggs United Kingdom	7	468 1.7×	130 0.6×	40 0.5×	126 2.5×	39 0.8×	8	650
Graham D. Spacey United Kingdom	8	269 1.0×	116 0.6×	86 1.0×	60 1.2×	47 1.0×	11	424
I. Kärkkäinen Finland	7	323 1.2×	65 0.3×	83 0.9×	153 3.0×	58 1.2×	7	582
Miriam Lee South Korea	16	261 1.0×	233 1.1×	52 0.6×	64 1.3×	161 3.4×	27	708

Countries citing papers authored by I M Kramer

Since Specialization

Citations

This map shows the geographic impact of I M Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I M Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I M Kramer more than expected).

Fields of papers citing papers by I M Kramer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I M Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I M Kramer. The network helps show where I M Kramer may publish in the future.

Co-authorship network of co-authors of I M Kramer

This figure shows the co-authorship network connecting the top 25 collaborators of I M Kramer. A scholar is included among the top collaborators of I M Kramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I M Kramer. I M Kramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Kramer, I M, et al.. (2024). Safety and tolerability of anti-FcRn monoclonal antibody in thyroid autoimmunity. SHILAP Revista de lepidopterología. 341–357.

Chaigne-Delalande, Benjamin, Guerric Anies, I M Kramer, & Elisabeth Génot. (2007). Nonadherent cells switch to a Rac-mediated, SHIP regulated, Akt activation mode for survival. Oncogene. 27(13). 1876–1885. 8 indexed citations

Kramer, I M & Hans‐Peter Lipp. (2007). Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. Journal of Clinical Pharmacy and Therapeutics. 32(1). 1–14. 94 indexed citations

Tolboom, Tanja C. A., et al.. (2004). Correlation between expression of CD44 splice variant v8-v9 and invasiveness of fibroblast-like synoviocytes in an in vitro system.. PubMed. 22(2). 158–64. 9 indexed citations

Croft, Daniel R., et al.. (1998). Co-culture of synovial fibroblasts and differentiated U937 cells is sufficient for high interleukin-6 but not interleukin-1beta or tumour necrosis factor-alpha release. Lara D. Veeken. 37(2). 148–156. 18 indexed citations

Kramer, I M, et al.. (1991). TGF-beta 1 induces phosphorylation of the cyclic AMP responsive element binding protein in ML-CCl64 cells.. The EMBO Journal. 10(5). 1083–1089. 75 indexed citations

Bolscher, Ben G.J.M., Rob van Zwieten, I M Kramer, et al.. (1989). A phosphoprotein of Mr 47,000, defective in autosomal chronic granulomatous disease, copurifies with one of two soluble components required for NADPH:O2 oxidoreductase activity in human neutrophils.. Journal of Clinical Investigation. 83(3). 757–763. 77 indexed citations

Kramer, I M, R.L. van der Bend, Anton T. J. Tool, et al.. (1989). 1-O-Hexadecyl-2-O-methylglycerol, a Novel Inhibitor of Protein Kinase C, Inhibits the Respiratory Burst in Human Neutrophils. Journal of Biological Chemistry. 264(10). 5876–5884. 83 indexed citations

Kramer, I M, A. J. Verhoeven, R.L. van der Bend, Ron S. Weening, & Dirk Roos. (1988). Purified protein kinase C phosphorylates a 47-kDa protein in control neutrophil cytoplasts but not in neutrophil cytoplasts from patients with the autosomal form of chronic granulomatous disease.. Journal of Biological Chemistry. 263(5). 2352–2357. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact